Arena Pharmaceuticals has developed lorcaserin (Lorqess; Belviq; APD-356), the lead from a series of orally active, small-molecule 5-HT 2c agonists. Lorcaserin is indicated in the US where it would be marketed by licensee Eisai, as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial BMI of 30 kg/m2 or greater (obese) or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition (eg, hypertension, dyslipidemia and type 2 diabetes)
